Glaukos Corporation IPO Research Information

Glaukos Corporation IPO Advisory

Share this IPO Profile:

Smart Search

For IPO Boutique's "scale of 1 to 5" BUY rating on Glaukos Corporation, and our comprehensive analysis, click "Buy Market Research".

Company	Symbol	Price Range	Issue Price	Open	Shares	Trade Date
Glaukos Corporation	GKOS - NYSE	$13.00-$15.00	$18.00	$29.11	6 million	6/25/2015
Underwriter(s): J.P. Morgan, BofA Merrill Lynch, Goldman Sachs & Co.
Co-Manager(s): William Blair, Cantor Fitzgerald & Co.
Industry: Health Care
Filing(s): Filed 2015-05-12 Terms Added 2015-06-15 Amended Terms 2015-06-23

Glaukos Corporation Quote & Chart - Click for current quote - GKOS

About Glaukos Corporation (adapted from Glaukos Corporation prospectus):
They are an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, one of the world's leading causes of blindness.

This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.

IPO Boutique aggregates information on public companies and private companies, such as "GKOS" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.